SCHEMBL21325059

SCHEMBL21325059

CCc1nccc2c(OCC3CC3)c(F)ccc12

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ FFAR4 Q5NUL3 1/20 0.34
▸ ALOX5AP P20292 3/20 0.33
▸ FEN1 P39748 3/20 0.33
▸ CHUK O15111 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ HTR4 Q13639 3/20 0.32
▸ HTR2C P28335 2/20 0.32
▸ HTR7 P34969 2/20 0.32
▸ HTR2B P41595 2/20 0.32
▸ HTR3A P46098 2/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ PDE4A P27815 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ PARP15 Q460N3 1/20 0.31
▸ PARP10 Q53GL7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21325503 0.80 FFAR4 (0.33) FFAR4ALOX5APFEN1CHUKMAOA
SCHEMBL21534011 0.77 HTR2C (0.36) FFAR4ALOX5APFEN1HTR4HTR2C
SCHEMBL21690528 0.77 RIPK1 (0.38) FFAR4ALOX5APFEN1HTR4HTR2C
SCHEMBL21690530 0.75 FFAR4 (0.38) FFAR4ALOX5APFEN1CHUKHTR4
SCHEMBL20376461 0.73 CYP1A2 (0.38) ALOX5APFEN1HTR4HTR2CHTR7
SCHEMBL20204677 0.71 PDE2A (0.37) FFAR4ALOX5APFEN1CHUKPDE4D
SCHEMBL21325050 0.71 HTR2B (0.35) FFAR4ALOX5APFEN1HTR4HTR2C
SCHEMBL21325057 0.70 RIPK1 (0.37) ALOX5APFEN1HTR4HTR2CHTR7
SCHEMBL21690529 0.70 ALOX5AP (0.34) FFAR4ALOX5APFEN1HTR4HTR2C
SCHEMBL20202028 0.69 PIK3R1 (0.39) FFAR4ALOX5APFEN1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 — — US disclosed
US-20200039966-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-06 — — US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039966-A1 URACIL CONTAINING COMPOUNDS UNG, DPYD, DUT PDE3B 3151/4885PDE3A 3001/4885FFAR4 4640/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT PDE3B 3151/4885PDE3A 3001/4885FFAR4 4640/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD PDE3B 2796/4885PDE3A 2801/4885FFAR4 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback